ライフサイエンスコーパス: antibody

1 fficacy of MEDI-573, an IGF-1/2-neutralizing antibody.

2 orrelation with the anti-carp PAV monoclonal antibody.

3 s FcgammaRs compared with the wild-type IgG1 antibody.

4 hed in mice administered with an anti-CXCL10 antibody.

5 the structure of the Fab fragment of such an antibody.

6 with in vivo administration of an anti-Ly6G antibody.

7 antibody, and anti-Ro/SS-A and anti-La/SS-B antibodies.

8 in viral diversity generated more efficient antibodies.

9 cts abrogated by neutralizing anti-IFN-gamma antibodies.

10 eatment with one or a cocktail of monoclonal antibodies.

11 mechanisms of virus infection inhibition by antibodies.

12 biotherapies such as vaccines and monoclonal antibodies.

13 designed to date have failed to elicit such antibodies.

14 oadly neutralizing, but not nonneutralizing, antibodies.

15 helping B cells to produce neutralizing IgG antibodies.

16 nificantly and increased protective specific antibodies.

17 n is also the primary target of neutralizing antibodies.

18 he in vivo protective activity of anti-HIV-1 antibodies.

19 Tspan5 has been limited by the lack of good antibodies.

20 d, limiting access to aggregation-modulating antibodies.

21 aces of HIV-1 particles are targeted by host antibodies.

22 ir strong cross-reactivity with anti-EMC-RBD antibodies.

23 ance, leading to the formation of inhibitory antibodies.

24 llular space to the potential of therapeutic antibodies.

25 other hand, the persistence of IgE blocking antibody 1 year after discontinuation might be an early

26 41 SOSIP Env trimers in complex with CD4 and antibody 17b, or with antibody b12, at resolutions of 3.

27 pathological pathway, we conjugated SOD with antibodies (Ab/SOD, size 10nm) to plasmalemmal vesicle-

28 n of viral variants that escape cellular and antibody (Ab)-mediated immune pressure, yet possess cont

29 us (DENV) endemic regions and cross-reactive antibodies (Abs) could potentially affect ZIKV pathogene

30 Antibodies (Abs) produced by immunoglobulin (IG) genes a

31 d the mechanism by which circulating anti-PE antibodies access cellular PE remains unknown.

32 IFN-gamma blocking antibody administered to Sphk2(-/-) mice or deletion of

33 antibody (AT1R-Ab) and anti-endothelial cell antibody (AECA).

34 -gD vaccine stimulated robust IgG1 and IgG2a antibodies after three vaccinations (P < 0.001).

35 rs old, serum concentrations of PFASs and of antibodies against diphtheria and tetanus were measured

36 -linked immunosorbent assays with monoclonal antibodies against PfLDH or PfIDEh showed detection limi

37 It is presently uncertain whether antibodies against V3 can interfere with the induction o

38 hepatocytes were isolated using a monoclonal antibody against a hepatic surface protein, leucine amin

39 of nerve fibers that reacted with a labeled antibody against calcitonin gene-related peptide (CGRP),

40 ous study suggested that the 18B7 monoclonal antibody against glucuronoxylomannan (GXM), the major co

41 Bevacizumab, a monoclonal antibody against VEGF, improves the proportion of patien

42 trans or in cis, that is shared with a BTLA antibody agonist.

43 say (ELISA) for PEG by tethering an anti-PEG antibody (AGP3) via tethers with different dimensions on

44 f influenza virus infections have shown that antibodies alone are sufficient to provide broad protect

45 fied by immunohistochemistry using the CM2B4 antibody alone, represent a more aggressive subtype that

46 40E8 and p396) and C-terminal half (4E4) tau antibodies also reduced tau uptake despite removing less

47 ation titers against 16 broadly neutralizing antibodies and 30 sera from chronic clade C infections.

48 Using receptor-blocking antibodies and activation peptides, we determined that t

49 /or therapeutic vaccines to boost functional antibodies and assist in eliminating the latent reservoi

50 luorescence staining with anti-alpha-tubulin antibodies and cell cycle analysis indicated that tubuli

51 ion secreted and membrane-bound single-chain antibodies and identify antibodies that can replace eith

52 Self-reactive antibodies and parasite-specific IgG in female Soay shee

53 al influenza viruses influenced HAI-specific antibodies and protective efficacy using a broadly prote

54 nent of the eye's vitreous, with therapeutic antibodies and proteins.

55 Binding of specific monoclonal anti-DARC antibodies and recombinant DBP to CD71(high)/RNA(high) r

56 F) conformation is a target for neutralizing antibodies and therefore an attractive antigen candidate

57 e impact of the presenting anti-ADAMTS13 IgG antibody and ADAMTS13 antigen on mortality.

58 articles heavily decorated with anti-ERalpha antibody and horseradish peroxidase (MP-Ab-HRP) were use

59 vivo Fab arm exchange leading to bispecific antibody and off-target effects.

60 flaviviruses that share cross-reactivity in antibody and T cell responses, and co-circulate in incre

61 ls is of critical importance but mast cells, antibodies, and basophils have few or no nonredundant ro

62 s have been associated with T cell-dependent antibodies, and their importance in both humans and mous

63 rs including renal disease, antiphospholipid antibody, and anti-Ro/SS-A and anti-La/SS-B antibodies.

64 Six patients had hepatitis B surface antibody (anti-HBs) titres above 10 mIU/mL at the end of

65 xysilane coated magnetite nanoparticles with antibody (antiHER2/APTMS-Fe3O4), as a platform bioconjug

66 Antibodies are critical components of the human adaptive

67 Anti-Flavivirus antibodies are highly cross-reactive and may facilitate

68 nst malaria and further shows IgG3 and GLURP antibodies are key in the OP mechanism, thus giving furt

69 rved already at 1 month of age, when the IgA antibodies are predominantly maternally derived in breas

70 Within this framework, protoxin-neutralizing antibodies are the key effector molecules while a shift

71 Clinical parameters analyzed were: HLA antibodies at transplant, de novo donor-specific antibod

72 sence of anti-angiotensin II type 1 receptor antibody (AT1R-Ab) and anti-endothelial cell antibody (A

73 n complex with CD4 and antibody 17b, or with antibody b12, at resolutions of 3.7 A and 3.6 A, respect

74 Studies employing immunofluorescence antibody-based assays reveal no changes in H3K4me3 level

75 technical validation of a rabbit monoclonal antibody-based sandwich immunoassay for human ERFE.

76 icant importance to the development of novel antibody-based therapies, and heavy chain (Hc) heterodim

77 c disease had increased titers of cow's milk antibodies before the appearance of anti-TG2A or celiac

78 me; however, the significance of circulating antibodies before transplant remains unclear.

79 Increased titers of cow's milk antibody before anti-TG2A and celiac disease indicates t

80 e charge-transfer resistance decreased after antibody binding, because there was an additional amount

81 erplay between the carbohydrate receptor and antibody binding, we conducted hemagglutination inhibiti

82 Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B (TcdB), reducing

83 -time-PCR analysis followed by inhibitor and antibody-blocking assays revealed that the arthropod HSP

84 Understanding how broadly neutralizing antibodies (bnAbs) to HIV envelope (Env) develop during

85 ew generation of potent broadly neutralizing antibodies (bNAbs).

86 Bispecific antibodies (bsAbs) are of significant importance to the

87 correlation with the anti-cod PAV polyclonal antibody, but no correlation with the anti-carp PAV mono

88 vaccine trial indicate that non-neutralizing antibodies can contribute to protection.

89 Although dengue virus (DENV) antibodies can neutralize or enhance Zika virus (ZIKV) i

90 nd PN were stained with monoclonal anti-PSMA antibody (clone 3E6, 1:100, M3620).

91 th tier 2 HIV-1 neutralization, and anti-H2A antibody clones were found to neutralize HIV-1.

92 d biotin-ligand and visualized with anti-FAM antibody-coated gold nanoparticles.

93 However, not every virus-antibody combination results in complete neutralization

94 on extensive structural analyses of antigen-antibody complexes.Single-particle electron cryomicrosco

95 tant to antibody neutralization despite high antibody concentrations.

96 eceived >/=1 prior therapy with an anti-CD20 antibody-containing regimen were treated with 560 mg ibr

97 Anti-Notch2 antibodies decreased MZ B cells in control and Notch2HCS

98 METHODS AND We combined a model of specific antibody deficiency, B cell-specific CD79a-Cre x XBP1 (X

99 ese studies support DNA-delivered monoclonal antibodies delivery as a potential strategy to augment t

100 There is growing interest in utilizing antibody-dependent cellular cytotoxicity (ADCC) to elimi

101 bs, readily induced by vaccines, can trigger antibody-dependent cellular effector functions, through

102 tate Zika virus (ZIKV) infection through the antibody-dependent enhancement (ADE) mechanism.

103 SEFL mutations eliminated off-target antibody-dependent monocyte phagocytosis of cynomolgus m

104 into the recognition mechanisms facilitating antibody design.

105 most of the broadly prevalent, neutralizing antibodies did not bind, conferred a selective advantage

106 otected mice after treatment with a blocking antibody directed against PD-1.

107 estigated whether benralizumab, a monoclonal antibody directed against the alpha subunit of the inter

108 Bevacizumab, a monoclonal antibody directed against VEGF, improves outcomes when a

109 nfectious pathogens.DNA-delivered monoclonal antibodies (DMAbs) can be produced by muscle cells in vi

110 pyrrolobenzodiazepine (PBD)-based anti-CD19 antibody drug conjugate (ADC) being investigated for tre

111 and unusual story of GO, which was the first antibody-drug conjugate approved for human use by the FD

112 Vadastuximab talirine (SGN-CD33A, 33A) is an antibody-drug conjugate consisting of pyrrolobenzodiazep

113 Current strategies to produce homogeneous antibody-drug conjugates (ADCs) rely on mutations or ine

114 oading on a per-vehicle basis as compared to antibody-drug conjugates (ADCs).

115 ncers (TNBCs), may be a potential target for antibody-drug conjugates.

116 Development of donor-specific antibodies (DSA) after lung transplantation is associate

117 bodies at transplant, de novo donor-specific antibodies (DSA), antibody-mediated rejection (AMR), acu

118 We hypothesized that de novo donor-specific antibody (DSA) causes complement-dependent endothelial c

119 Here, we characterize how an anti-idiotypic antibody (E1) binds antibody HM14c10, which potently neu

120 crystal structures of Pfs25 in complex with antibodies elicited by immunization via Pfs25 virus-like

121 ty-matured human NANP-reactive memory B cell antibodies elicited by natural Pf exposure that potently

122 se variants were not efficiently detected by antibodies elicited by the wild-type HA from viruses sel

123 The antibody extensively anchors two monomers together at th

124 cles that are functionalized with anti MC-LR antibody Fab' fragments for the selective capture of MC-

125 pecially for these samples without available antibodies for enrichment.

126 combined with immunodetection with specific antibodies for gliadins, gamma-gliadins, LMW subunits an

127 Applying this antibody for protein expression profiling in 44 normal a

128 the pharmacokinetics of the Alexa750-labeled antibody formats showed shorter blood half-times and hig

129 -diversity phage display library to engineer antibody fragments (Fabs) that can modulate the activity

130 todomain of Lassa GP bound to a neutralizing antibody from a human survivor at 3.2-angstrom resolutio

131 have the likely evolutionary precursors, the antibody gene deaminase AID and the RNA/DNA editing enzy

132 ses aberrant insertions by releasing cleaved antibody gene fragments that subsequently reintegrate in

133 Passive immunization using Abeta-specific antibodies has been demonstrated to reduce amyloid depos

134 The existence of catalytic antibodies has been known for decades.

135 asion assays, binding-inhibitory activity of antibodies has been reported to be associated with prote

136 teractions between antigens and the elicited antibodies has limited their success thus far.

137 ctures, and specific modification of natural antibodies has proven quite challenging.

138 rstanding the developmental pathway of these antibodies has provided insights into their precursors,

139 Antibodies have become an indispensable tool for many bi

140 Antibodies have complex multistranded architectures, and

141 These antibodies have evolved to recognize the dense array of

142 ional monoclonal antibodies, many bispecific antibodies have issues regarding production, stability,

143 reen, isolate, and characterize HIV-specific antibodies have led to the identification of a new gener

144 ze how an anti-idiotypic antibody (E1) binds antibody HM14c10, which potently neutralizes DENV seroty

145 ard broader practical delivery of monoclonal antibody immunotherapeutics for additional infectious pa

146 anzees and generate broad cross-neutralizing antibodies in animals and humans.

147 nosensor, capable of identifying circulating antibodies in real time, can also be applied in the diag

148 8-2014 on the kinetics of maternal pertussis antibodies in unvaccinated women and their infants (grou

149 ells were activated with antigen or anti-CD3 antibody in the outer chamber.

150 upport the potential therapeutic use of this antibody in the treatment of systemic amyloidosis.

151 pported the production of virus-neutralizing antibodies independently of the classical MHC haplotype.

152 otent, highly selective humanized monoclonal antibody inhibitor of MMP9, has shown promise in treatin

153 vo DSA emergence, whereas the persistence of antibodies is predicted by DSA strength and specificity.

154 The hydrophobicity of a monoclonal antibody is an important biophysical property relevant f

155 tained to ensure generation of high-affinity antibody is unknown.

156 rgen by the immune system, especially by IgE antibodies, is prevented.

157 Omalizumab, an anti-IgE antibody, is used to treat patients with severe allergic

158 F59/SF-2 rgp120 vaccine had higher-magnitude antibody levels than adults (gp120 median FIs of 15,509

159 red between the cohorts, and that changes in antibody levels to Apical Membrane Antigen 1 suggested a

160 Antibody levels were assessed at birth, day (D) 43, and

161 day 4 post-challenge, we measured increased antibody levels, ASCs and HAI titers with reduced viral

162 marked reduction in TFH cell numbers and IgE antibody levels, but type 2 cytokine responses and eosin

163 ically the research related to intracellular antibodies, link this to the TRIM21 effector mechanism,

164 Agonistic monoclonal antibodies (mAb) targeting the T-cell receptor coregulat

165 Competitive binding of the human monoclonal antibody (mAb) LE2E9 revealed overlapping epitopes with

166 Monoclonal antibodies (mAbs) targeting Notch protein activity have

167 Using a panel of monoclonal antibodies (MAbs) that recognize known major antigenic s

168 of antiviral therapies, including monoclonal antibodies (mAbs), have naturally relied extensively on

169 antigenicity using four different monoclonal antibodies (MAbs), including PGT151.

170 at NP contain elevated levels of B cells and antibodies, making NP an ideal system for studying B cel

171 ential to outperform conventional monoclonal antibodies, many bispecific antibodies have issues regar

172 ics represents an important mechanism during antibody maturation in vivo.

173 hat engage them, as well as defined how such antibodies mature to acquire breadth.

174 versing immune exhaustion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1

175 fter lung transplantation is associated with antibody mediated rejection, acute cellular rejection, a

176 Antibody-mediated CD4(+) T-cell depletion in HF mice (st

177 renal allograft injury in a model of severe antibody-mediated damage in highly sensitized recipients

178 loxed mice (XBP1-conditional knockout), with antibody-mediated depletion of CD4+ T cells.

179 Furthermore, antibody-mediated depletion of T cells prevented nasopha

180 Antibody-mediated phagocytosis is an important immune ef

181 K) cells localize in the microcirculation in antibody-mediated rejection (AMR) and have been postulat

182 Antibody-mediated rejection (AMR) is an increasingly rec

183 nt, de novo donor-specific antibodies (DSA), antibody-mediated rejection (AMR), acute cellular reject

184 antidonor antibodies results in accelerated antibody-mediated rejection (AMR), complement activation

185 ing list patients and a better prediction of antibody-mediated rejection.

186 eloped high titers of broadly cross-reactive antibodies; mice and ferrets exhibited narrower humoral

187 an help improve blood safety by reducing the antibody negative window period in blood donors in resou

188 fraction of virus particles are resistant to antibody neutralization despite high antibody concentrat

189 presence of sputum anti-EPX and anti-nuclear antibodies of the IgG subtype.

190 ls to NK cell cytotoxicity when neutralizing antibody of PD-1 or PD-L1 was added.

191 therapy to a similar degree as PD-1 blocking antibodies, offering a next-generation approach in the d

192 Anchoring anti-PEG antibodies on cells via variable-length tethers for cell

193 suggest that clinicians should consider IgM antibody or polymerase chain reaction testing for Zika v

194 The use of the licensed antibody palivizumab, which recognizes site II on both t

195 glec-8 in combination with integrin blocking antibodies, pharmacologic inhibitors, phosphoproteomics,

196 re fabricated using well-defined full-length antibody-polymer conjugates (APCs).

197 ely charged CDR mutations that are linked to antibody polyspecificity.

198 An antibody prevalence in epilepsy (APE) score based on cli

199 on between GDF15 and GFRAL with a monoclonal antibody prevented the metabolic effects of GDF15 in rat

200 Antibody production and the frequency of antibody-secret

201 acquisition of adaptive immune responses and antibody production in response to foreign antigens.

202 f the most critical steps in hapten-specific antibody production.

203 Here, we describe how F-specific antibodies protect against RSV and why specifically targ

204 died from anoxia, more likely to be HCV and antibody reacting to hepatitis B core antigen+, and less

205 o a standard immunoassay, in a 6 min protein-antibody reaction.

206 ion of allergic disease independent of their antibody reactivity, is still lacking.

207 Emicizumab is a bispecific antibody recognizing both the enzyme factor IXa and the

208 The antibodies reduced tau uptake in an epitope-dependent ma

209 d airways, early induction of virus specific antibodies, reduced levels of pro-inflammatory cytokines

210 an overview of ongoing research on mAbs and antibody-related theranostics in preclinical and clinica

211 incompatible renal transplant performed with antibody removal and conventional immunosuppression cont

212 dies have demonstrated that broadly reactive antibodies require Fc-Fc gamma receptor interactions for

213 Antibody-resistant strains arising through further gene

214 safe and effective and induces an increased antibody response compared with standard influenza vacci

215 more potent secondary anti-RABV neutralizing antibody response than rLBNSE-immunized mice.

216 rhesus macaques elicited a rapid and robust antibody response, conferring complete protection upon c

217 ve of not significantly boosting the mucosal antibody response, it augmented the frequency of IFN-gam

218 rapid elicitation of broad and potent serum antibody responses in all four cows.

219 lade 2.3.4) vaccine to elicit cross-reactive antibody responses to these emerging viruses.

220 uced H3-specific hemagglutination inhibition antibody responses, and consequently might affect vaccin

221 d CCL28 induces significantly higher mucosal antibody responses, involved in providing long-term cros

222 Ebola vaccine candidate elicited anti-Ebola antibody responses.

223 on into sensitized recipients with antidonor antibodies results in accelerated antibody-mediated reje

224 Concordance between 4 antibodies revealed regression for tumor tissue cores (R

225 equencing experiments using an anti-O-GlcNAc antibody revealed significant chromatin enrichment of O-

226 Antibody production and the frequency of antibody-secreting cells were significantly elevated in

227 ndrial homeostasis and alterations in GC and antibody-secreting cells.

228 ed as a self-limiting infection and anti-HEV antibodies seem to protect against reinfection, its path

229 We are unable to comment on long-term antibody sensitisation effects.

230 imaging using a phospho-specific p-T153/Y155 antibody showed that phosphorylated TDP-43 was specifica

231 therapy to a similar degree as PD-1-blocking antibodies.Significance: These findings show how GSK-3 i

232 ast, there has been less systematic study of antibody specificities that must rely mainly or exclusiv

233 RSV vaccine and antibody strategies are likely to be cost-effective if t

234 terminal (Tau13) and middomain (6C5 and HT7) antibodies successfully prevented uptake of tau species,

235 Intra-articular anti-VEGF antibodies suppress OA progression, reduce levels of pho

236 benzodiazepine dimers linked to a monoclonal antibody targeting CD33, which is expressed in the major

237 cies, whereas the distal C-terminal-specific antibody (Tau46) had little effect.

238 ad significantly more anti-basement membrane antibodies than sera from patients with CRSwNP and contr

239 e structurally investigated two neutralizing antibodies that bind the attachment protein sigma1 of re

240 stimulus to boost HIV-1-specific functional antibodies that can eliminate HIV-1-infected cells.

241 e-bound single-chain antibodies and identify antibodies that can replace either Sox2 and Myc (c-Myc)

242 cent mouse lung fibroblasts and screened for antibodies that recognized senescence-associated cell-su

243 vaccination also induced serum-neutralizing antibodies that targeted similar epitope domains at the

244 We treated our patient with ustekinumab, an antibody that binds the p40 subunit of interleukin-23 an

245 programmed death-ligand 1 (PD-L1) monoclonal antibody that inhibits PD-L1 and programmed death-1 (PD-

246 mab is a novel, first-in-class, agonist CD27 antibody that stimulates the CD27 pathway, which results

247 r detection of Mycobacterium leprae-specific antibodies: the visual immunogold OnSite Leprosy Ab Rapi

248 luble ligands have commonly been targeted by antibody therapeutics for cancers and other diseases.

249 phenformin enhances the effect of anti-PD-1 antibody therapy on inhibiting tumor growth in the BRAF

250 ease category, previous exposure to anti-GD2 antibody therapy, and tumour MYCN amplification status.

251 epresent particularly attractive targets for antibody therapy.

252 ed by immobilization of biotinylated capture antibodies through a streptavidin bridge.

253 rates and lower hemagglutination-inhibition antibody titer geometric mean fold increase against infl

254 iruses 1 to 4 (DENV1-4), a specific range of antibody titer has been shown to enhance viral replicati

255 To mitigate the decline in measles virus antibody titers in IVIGs and to ensure consistent produc

256 directly compared and determine the minimal antibody titers required to halt transmission in differe

257 from all symptomatic dengue disease at high antibody titers.

258 Both models found that antibodies to 5 proteins of the Merozoite Surface Protei

259 ysium using an immunofluorescence assay, and antibodies to a deamidated gliadine peptide using an imm

260 ted the capacity of anti-receptor monoclonal antibodies to deliver vaccine components to skin DC subs

261 No neutralizing antibodies to evolocumab were detected.

262 viability of human neutrophils via agonistic antibodies to Fas and Siglec-9.

263 ore, this study investigated how preexisting antibodies to historical influenza viruses influenced HA

264 RV144 induced antibodies to HIV that were partially protective against

265 lly protective against infection, as well as antibodies to HSV.

266 antibodies to merozoites did not decline and antibodies to IE surface antigens expressing virulent ph

267 glycol thiols, neutravidin and biotinylated antibodies to immobilize bacteria.

268 In contrast, complement-fixing antibodies to merozoites did not decline and antibodies

269 ian time period of 10 years and analyzed for antibodies to tissue transglutaminase (anti-TG2A) using

270 chain reaction (PCR)- and the prevalence of antibodies to two P. falciparum antigens (MSP-1, AMA-1).

271 ple sclerosis (MS), we administered blocking antibody to CLEC12A that significantly ameliorated disea

272 protection and the failure of a neutralizing antibody to correlate with protection against dengue vir

273 In a second step, a second antibody to ERBB2 quantitatively detects the bound analy

274 n the spinal cord using a saporin-conjugated antibody to Mac1, we demonstrate a causal role for micro

275 te the utility of employing an anti-idiotype antibody to monitor a patient's specific immune response

276 he FOURIER trial of evolocumab, a monoclonal antibody to proprotein convertase subtilisin-kexin type

277 d that administration of cis P-tau targeting antibody to rodents reduces or delays pathological featu

278 The reactivity of IgE antibody to the extracted protein did not differ among t

279 ealed reduced vascular leak with alphavbeta5 antibody treatment.

280 d to be activated by donor-specific anti-HLA antibodies triggering their CD16a Fc receptors.

281 Commonly used methods to obtain novel antibodies typically yield several candidates capable of

282 ed to assess the persistence of bactericidal antibodies up to 4 years after a three-dose schedule of

283 -C2, derived from a camelid heavy-chain-only antibody (VHH).

284 mbinant variable domains of heavy-chain-only antibodies (VHHs) are becoming a salient option as immun

285 also generated prolonged virus-neutralizing antibodies (VNAs), resulting in better protection agains

286 The occurrence of anti-drug antibodies was similar in the treatment groups (five [2%

287 The stable effector functionLess (SEFL) antibody was designed as an IgG1 antibody with a constan

288 , intra-mPFC infusion of a BDNF-neutralizing antibody was performed to test the necessity of BDNF rel

289 Fumonisin-specific antibody was used to isolate mimotopes from a 12-mer pep

290 Polyclonal antibodies were generated against OTC molecule (anti-OTC

291 Antibodies were immobilized on the gold electrode surfac

292 Rates of antiphospholipid antibodies were low, comparable to those in controls, an

293 nal HNPs conjugated with anti-MG1 monoclonal antibodies were synthesized, and the coupling efficiency

294 rface-functionalized with polyclonal anti-M1 antibodies, which then serve to identify the universal b

295 activity upon stimulation with an anti-TREM2 antibody, which induces their homodimerization.

296 The T-11 COBRA HA vaccine elicited antibodies with HAI and neutralization activity against

297 We thus developed novel glycylation-specific antibodies with which we detected glycylation in many pr

298 Less (SEFL) antibody was designed as an IgG1 antibody with a constant region that lacks the ability t

299 re of the epitope recognized by a monoclonal antibody with opsonophagocytic activity and representati

300 ain that is accessible to extracellular ZnT8 antibody (ZnT8A).